Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction
Source : https://onlinelibrary.wiley.com/doi/10.1002/ehf2.13811
Magdy Abdelhamid , Corresponding Author Magdy Abdelhamid Faculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University, Cairo, Egypt Correspondence to: Magdy Abdelhamid, Faculty of Medicine, Kasr Al Ainy, Cardiology...
Relevance: Considering the magnitude of the problem and the expected benefit on the target population, an Egyptian consensus document was conducted to demonstrate the importance of and the critical knowledge needed for effective and safe implementation of SGLT2i in the daily practice for the management of patients with HFrEF.
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122000315?via=ihub
Empagliflozin proves benefit on health status in the non-diabetic, ethnic minority represented, EMPATROPISM trial population. * A significant mean improvement of 22 points in Kansas City Cardiomyopathy Questionnaire (KCCQ) was...
/>
Conclusions: Empagliflozin benefits quality of life in the non-diabetic, ethnic minority represented, EMPATROPISM trial population.
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35092583/
Introduction: AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure (HF). The safety and pharmacokinetics (PK) of AMG 986 in...
Conclusions: The results of this study support the enrollment of HF patients with RI to clinical trials of AMG 986 without the need for dose adjustments.
Mesenchymal Stromal Cell Exosomes in Cardiac Repair - Current Cardiology Reports
Source : https://link.springer.com/article/10.1007/s11886-022-01660-1
Purpose of the Review Mesenchymal stromal cells (MSCs) are considered an attractive option for cell-based therapy because of their immune-privileged phenotype and paracrine activity. Substantial preclinical evidence indicates that MSC...
Conclusion/Relevance: MSC Exosomes appear to be leading candidates to treat myocardial infarction and subsequent heart failure by carrying rich cargo from their parental cells. However, more clinical and pre-clinical studies on MSC exosomes will be required to confirm the beneficial effect to treat cardiovascular diseasesinterventions for...
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-022-00985-0
Purpose of Review This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings.
Conclusion: Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.